Peregrine’s lung cancer immunotherapy gets onto FDA fast track
The lead immunotherapy candidate from Peregrine Pharmaceuticals, bavituximab, has been designated by the FDA for fast-tracked appraisal.
Being a potential treatment for an unmet need of a serious, life-threatening condition – non-small cell lung cancer (NSCLC) – the late-stage drug may reach market more quickly because of the designation.
The company recently started its pivotal phase three SUNRISE trial to compare the addition of bavituximab, a monoclonal antibody, to docetaxel versus using the chemotherapy drug alone.
US FDA grants Peregrine fast track designation for bavituximab in NSCLC (The Pharma Letter).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.